Published on
October 16, 2025
- 14:15 GMT
Phase Advance and QNova Capital Forge Alliance to Usher in AI-Driven, Non-Animal Drug Development Era
Predictive AI modeling startup and biotech-focused venture fund unite to accelerate next-generation therapeutics and reshape the FDA regulatory path. SAN DIEGO, CA, UNITED STATES, October 16, 2025 /EINPresswire.com/ -- Phase Advance, a pioneering AI company capable of predicting drug performance through Phase 3 clinical outcomes for new therapeutics with only their discovery details, has entered a strategic alliance with QNova Capital, the new venture fund of QNova LifeSciences. Together, they aim to …
Distribution channels:
Business & Economy, Healthcare & Pharmaceuticals Industry
...